Hologic, Inc. Recalls Biozorb Marker Due To Reported Complications And Adverse Events With Implanted Devices - FDA
$HOLX
Medical Electronics
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $95.00 → $85.00 | Buy → Neutral | Citigroup |
| 6/27/2024 | $87.00 | Overweight | Stephens |
| 4/3/2024 | $80.00 → $95.00 | Neutral → Buy | Citigroup |
| 7/14/2023 | $95.00 | Hold → Buy | Needham |
| 12/7/2022 | $75.00 | Sector Perform | RBC Capital Mkts |
| 10/13/2022 | $75.00 | Buy | Mizuho |
| 7/20/2022 | $73.00 | Neutral | UBS |
| 7/20/2022 | $81.00 → $75.00 | Buy → Neutral | BofA Securities |
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
– Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 28, 2024. "We delivered strong fiscal 2024 results, reinforcing our track record of durable performance with another solid quarter of growth," said Steve MacMillan, Hologic's chairman, president, and chief executive officer. "Each year we grow stronger, leveraging our
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4567924. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.ho
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 29, 2024. "In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Our strong fiscal qua
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21st, at 10 a.m. Central Time (CT). 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on Tuesday, December 3rd, at 2:10 p.m. Eastern Time (ET). Citi's 2024 Global Healthcare Conference in Miami, FL on Wednesday, December 4th, at 8:45 a.m. ET. Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic's website at http://investors.hologic.com. The webcasts will be available for 30 days following each event. Abou
– Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 28, 2024. "We delivered strong fiscal 2024 results, reinforcing our track record of durable performance with another solid quarter of growth," said Steve MacMillan, Hologic's chairman, president, and chief executive officer. "Each year we grow stronger, leveraging our
Hologic, Inc. (NASDAQ:HOLX), a global champion of women's health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women's health for approximately $350 million, subject to working capital and other customary closing adjustments. Gynesonics, which is based in Redwood City, California, develops and sells the Sonata® System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata System combines real-t
Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
BERWYN, Pa., Feb. 11, 2021 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that its Board of Directors has appointed Karleen Oberton as a new director of the Company. Ms. Oberton serves as Chief Financial Officer of Hologic, Inc. (NASDAQ: HOLX), an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment systems. "We are pleased to welcome Karleen to AMETEK as a member of our Board of Directors," commented David A. Zapico, AMETEK Chairman and Chief Executive Officer. "Karleen is a skilled business executive with more than 30 years of experience in public accounting, biotechnology and medical device m
Citigroup downgraded Hologic from Buy to Neutral and set a new price target of $85.00 from $95.00 previously
Stephens initiated coverage of Hologic with a rating of Overweight and set a new price target of $87.00
Citigroup upgraded Hologic from Neutral to Buy and set a new price target of $95.00 from $80.00 previously
Hologic (NASDAQ:HOLX) has outperformed the market over the past 20 years by 6.31% on an annualized basis producing an average annual return of 14.81%. Currently, Hologic has a market capitalization of $18.13 billion. Buying $100 In HOLX: If an investor had bought $100 of HOLX stock 20 years ago, it would be worth $1,541.14 today based on a price of $77.69 for HOLX at the time of writing. Hologic's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revie
Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:HOLX) with a In-Line and lowers the price target from $78 to $76.
Hologic's (NYSE:HOLX) short percent of float has fallen 8.59% since its last report. The company recently reported that it has 4.64 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.77 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod
For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump